A. S. Galieva
Research Subjects
A. S. Galieva has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- A. G. Plieva1 shared publication
- Alexander Sannikov
Department of Psychiatry, Rostov State Medical University, 344022 Rostov-on-Don, Russia
1 shared publication - J. N. Kuznetsova1 shared publication
- Stanislav Rodkin
Research Laboratory “Medical Digital Images Based on the Basic Model”, Department of Bioengineering, Institute of Living Systems, Don State Technical University, Rostov-on-Don 344000, Russia
1 shared publication - V. A. Zdorovtsova1 shared publication
- V. G. Zaika
Rostov State Medical University
1 shared publication
Latest Publications
- 30 November 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 12,p. 1383-1391
Psychopharmacotherapy of affective disorders in patients with chronic kidney disease receiving therapy with programmed hemodialysis
Affective disorders such as depression and anxiety occur in a significant proportion of patients with chronic kidney disease, especially those who receive programmed hemodialysis therapy. According to epidemiological studies, depression is detected from 20 to 40% in patients on hemodialysis, and the level of anxiety disorders reaches from 25 to 50%. Treatment of affective disorders in patients with chronic kidney disease is complicated by changes in the pharmacokinetics and pharmacodynamics of drugs. In patients receiving hemodialysis treatment, the glomerular filtration rate is reduced, which affects the excretion of drugs and requires dosage adjustments, especially when using antidepressants and anxiolytics. In this regard, the issue of choosing safe and effective psychopharmacotherapy regimens remains extremely relevant in the treatment of depressive and anxiety disorders in patients with chronic kidney disease. The purpose of the review: to analyze the effectiveness and safety of psychopharmacotherapy of affective disorders in patients with chronic kidney disease receiving programmed hemodialysis therapy, as well as to provide modern treatment regimens taking into account the specifics of metabolism and drug excretion in this category of patients.
- 30 November 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 12,p. 1383-1391
Psychopharmacotherapy of affective disorders in patients with chronic kidney disease receiving therapy with programmed hemodialysis
Affective disorders such as depression and anxiety occur in a significant proportion of patients with chronic kidney disease, especially those who receive programmed hemodialysis therapy. According to epidemiological studies, depression is detected from 20 to 40% in patients on hemodialysis, and the level of anxiety disorders reaches from 25 to 50%. Treatment of affective disorders in patients with chronic kidney disease is complicated by changes in the pharmacokinetics and pharmacodynamics of drugs. In patients receiving hemodialysis treatment, the glomerular filtration rate is reduced, which affects the excretion of drugs and requires dosage adjustments, especially when using antidepressants and anxiolytics. In this regard, the issue of choosing safe and effective psychopharmacotherapy regimens remains extremely relevant in the treatment of depressive and anxiety disorders in patients with chronic kidney disease. The purpose of the review: to analyze the effectiveness and safety of psychopharmacotherapy of affective disorders in patients with chronic kidney disease receiving programmed hemodialysis therapy, as well as to provide modern treatment regimens taking into account the specifics of metabolism and drug excretion in this category of patients.